



**Jürgen Bader**

**Contact**

Jürgen Bader

## Publications (3)

Driessen C, Hess D, von Moos R, Pabst T, Huitema A, Sessa C, Overkleeft H, Berthod G, Hawle H, Xyrafas A, Berset C, Hitz F, Bader J, Rosing H, Jörger M, Kraus M, Mey U. Treatment with the HIV protease inhibitor nelfinavir triggers the unfolded protein response and may overcome proteasome inhibitor resistance of multiple myeloma in combination with bortezomib: a phase I trial (SAKK 65/08). *Haematologica* 2015; 101:346-55.

Kraus J, Kraus M, Liu N, Besse L, Bader J, Geurink P, de Bruin G, Kisselev A, Overkleeft H, Driessen C. The novel  $\beta$ 2-selective proteasome inhibitor LU-102 decreases phosphorylation of I kappa B and induces highly synergistic cytotoxicity in combination with ibrutinib in multiple myeloma cells. *Cancer Chemother Pharmacol* 2015; 76:383-96.

Kraus M, Müller-Ide H, Rückrich T, Bader J, Overkleeft H, Driessen C. Ritonavir, nelfinavir, saquinavir and lopinavir induce proteotoxic stress in acute myeloid leukemia cells and sensitize them for proteasome inhibitor treatment at low micromolar drug concentrations. *Leuk Res* 2013; 38:383-92.

## Projects (1)

**Improving the activity of proteasome inhibitors for potential treatment of**

*Fundamental Research - Mar 31, 2015 - Dec 7, 2018*

*Automatically Closed*

---

Kantonsspital St.Gallen

Rorschacher Strasse 95

CH-9007 St.Gallen

T: +41 71 494 11 11

[support.forschung@kssg.ch](mailto:support.forschung@kssg.ch)